|
5/8/2013 7:51:27 AM
|
POZEN Inc. Posts Q1 Loss Per Share Of $0.19 Vs. Loss $0.28 Last Year
|
|
4/18/2013 9:00:18 AM
|
|
|
3/27/2013 10:32:21 PM
|
|
|
3/27/2013 7:38:43 AM
|
|
|
3/27/2013 7:33:09 AM
|
POZEN Submits NDA To FDA For PA32540/PA8140
|
|
3/19/2013 11:01:12 AM
|
|
|
3/6/2013 10:00:41 AM
|
|
|
3/6/2013 7:41:02 AM
|
|
|
3/6/2013 7:32:26 AM
|
POZEN Posts Q4 Loss/Share Of $0.20 Vs. Profit $2.05 Last Year
|
|
2/11/2013 3:43:26 AM
|
|
|
2/8/2013 7:48:55 AM
|
|
|
2/8/2013 7:32:12 AM
|
POZEN Presents Positive PA32540 Phase 3 Data At 2013 International Stroke Conference
|
|
11/27/2012 9:51:36 AM
|
|
|
11/15/2012 4:28:33 PM
|
POZEN Announces Positive Results For PA8140-102 Bioavailability Study
|
|
11/8/2012 8:37:46 AM
|
|
|
11/8/2012 7:49:31 AM
|
POZEN Posts Q3 Loss/Share Of $0.19 Vs. Loss $0.24 Last Year
|
|
11/6/2012 6:05:31 PM
|
POZEN Presents Positive PA32540 Pivotal Phase 3 Data At American Heart Association Scientific Sessions 2012
|
|
10/1/2012 4:46:37 PM
|
|
|
10/1/2012 4:34:18 PM
|
POZEN Patents Upheld In Treximet Patent Litigation Appeal
|
|
9/6/2012 2:16:50 PM
|
|